Investors & Media

RESTEM Provides Corporate Update and Announces Key Business Objectives for 2025

RESTEM Receives FDA Fast Track Designation for Restem-L for Idiopathic Inflammatory Myopathy

RESTEM Receives FDA Orphan Drug Designation for its ULSC Program for the Treatment of Polymyositis and Dermatomyositis

RESTEM Presents Phase 1 Data of its ULSC Program in Polymyositis/ Dermatomyositis at ACR Convergence 2024

RESTEM Launches NK Cell Therapy Program with Publication of Results from Clinical Study of NK Cell Therapy Targeting Senescence and Age-Associated Disorders

RESTEM and JAR of Hope Foundation Announce Strategic Partnership and Clinical Trial Launch of Next-Generation Cell Therapy for Patients with Duchenne Muscular Dystrophy

UF Center for Regenerative Medicine recruiting for trial on potential therapy for autoimmune disorders

FDA approves COVID-19 trial after successful emergency use of umbilical stem cells from RESTEM